JPMORGAN CONFERENCE JANUARY 12-15 2026 SAN FRANCISCO //..// LURBINECTEDIN / IMFORTE / ROCHE . Let's Hope ROCHE Can Provide The MARKET With The Actual Percentage Of Patients Who, After Being Treated As FIRST-LINE INDUCTION THERAPY For SMALL CELL LUNG CANCER With ATEZOLIZUMAB ... Will Actually Be Able To Access MAINTENANCE THERAPY With IMFORTE .

HOY LUNES PRESENTACIÓN DE ROCHE Y AMGEN  .

MAÑANA MARTES PRESENTACIÓN DE JAZZPHARMA .

POR SU PARTE PHARMAMAR VA ... PERO SIN PRESENTACIÓN ANUNCIADA QUE CONSTE ...

JP MORGAN 2026 // LURBINECTEDIN / ATEZOLIZUMAB / IMFORTE / ROCHE .

 
ESPEREMOS QUE ROCHE HOY PUEDA PROPORCIONAR AL MERCADO EL PORCENTAJE REAL DE PACIENTES QUE , TRAS RECIBIR ATEZOLIZUMAB COMO TRATAMIENTO DE INDUCCIÓN DE PRIMERA LÍNEA PARA EL SMALL CELL LUNG CANCER ... PODRÁN ACCEDER REALMENTE A LA TERAPIA DE MANTENIMIENTO CON IMFORTE / LURBINECTEDIN TRAS EL DESCARTE DE EST@S PACIENTES :

*.- L@S PACIENTES TRATADOS CON DURVALUMAB ... 

**.- L@S PACIENTES CON METÁSTASIS ...

***.- L@S PACIENTES CON COMORBILIDADES SERIAS ...

****.- L@S PACIENTES A LOS QUE EL TUMOR HA PROGRESADO ...

*****.- L@S PACIENTES QUE ELEGIRAN PASAR DE MANTENIMIENTO CON IMFORTE DADOS LOS EVENTOS ADVERSOS QUE PROVOCA Y ELEGIRAN PASAR DIRECTAMENTE A  SER TRATADOS EN SEGUNDA LINEA CON TARLATAMAB ... QUE EN SEGUNDA LINEA APORTA UNA OVERALL SURVIVAL DE + 13,6 MESES ...

******.- L@S PACIENTES QUE VOLUNTARIAMENTE RECHAZEN SER TRATADOS Y ELIJAN TRATAMIENTOS DE CONFORT ...

TANTO ROCHE COMO JAZZPHARMA COMO PHARMAMAR EVITAN DAR NUMERO DE PACIENTES QUE PODRIAN IR A MANTENIMIENTO CON LURBINECTEDIN / IMFORTE ... Y LOS SABEN .

QUESTIONS THAT ANALYSTS ATTENDING JPMORGAN-26 SHOULD ASK :

.

*.- TO JAZZ PHARMA : What Are The Realistic Expectations Regarding The Position Of LURBINECTEDIN As A SECOND-LINE Treatment After The FULL APPROVAL Of AMGEN’s TARLATAMAB by the FDA, Once it Becomes The STÁNDARD TREATMENT FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER ( ES-SCLC ) In The 2L Setting, CONSIDERING  THAT LURBINECTEDIN CURRENTLY HAS ONLY CONDITIONAL APPROVAL BASED ON Phase II RESULTS FROM HEALTH AUTHORITIES ? .

*.- TO PHARMAMAR : What Are The Realistic Expectations For The Completion Of The Phase III LAGOON Trial, Given That It Was Initiated On July 22, 2022 ? .

*.- TO JAZZ PHARMA : WHAT EXPLANATIONS CAN BE PROVIDED REGARDING THE CURRENT STATUS Of POTENCIAL LURBINECTEDIN GENERICS / BÍOSIMILARS ... ? .

*.- TO PHARMAMAR : Can They Explain Whether They Are 100% Confident That IMFORTE WILL BE APPROVED BY THE EUROPEAN MEDICINES Agency Solely Because It Was APPROVED BY THE FDA, Knowing That These Are Two Independent Evaluations With No Direct Correlation .